AIM ImmunoTech Inc. (NYSE American: AIM) is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The company's flagship products include Ampligen® (rintatolimod), a dsRNA drug approved in Argentina for severe chronic fatigue syndrome (CFS), and Alferon N Injection®, approved in the U.S. for refractory or recurring external genital warts. AIM is actively pursuing clinical trials for Ampligen in various oncology indications (e.g., pancreatic, ovarian, breast cancer) and as a potential therapeutic for Long COVID and Post-COVID Conditions.
The Ocala headquarters serves as the principal executive and administrative office, overseeing research and development strategy, clinical trial management, financial operations, and corporate governance.
The facility is likely a modern office space equipped to support biopharmaceutical operations, including administrative functions and coordination of external research and manufacturing.
As a clinical-stage biopharmaceutical company, the work culture likely emphasizes scientific rigor, innovation, collaboration with research institutions, and a strong focus on achieving clinical milestones and regulatory approvals.
The headquarters is central to AIM ImmunoTech's strategic decision-making, investor relations, and the coordination of its global clinical development programs for its drug candidates.
While headquartered in the United States, AIM ImmunoTech has a global outlook, particularly in its clinical trial operations and drug approvals. Ampligen is approved in Argentina, and the company actively conducts or supports clinical trials in multiple countries, including sites in Europe for its oncology and Long COVID programs. Their strategy involves seeking regulatory approvals and potential commercialization partnerships in various international markets.
2117 SW Highway 484
Ocala
Florida
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AIM ImmunoTech' leadership includes:
AIM ImmunoTech has been backed by several prominent investors over the years, including:
Over the past year, AIM ImmunoTech notably strengthened its financial leadership with the appointment of W. Charles Barker as Chief Financial Officer in August 2023, succeeding the previous CFO.
Discover the tools AIM ImmunoTech uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
AIM ImmunoTech likely uses standard corporate email formats. Common patterns include first initial followed by last name, or first name followed by last name. Given its size, simpler formats are probable.
[first_initial][last]@aimimmuno.com
Format
tequels@aimimmuno.com
Example
70%
Success rate
GlobeNewswire • May 20, 2024
AIM ImmunoTech announced the publication of preclinical data in the American Journal of Cancer Research, demonstrating Ampligen's (rintatolimod) potential in treating pancreatic cancer. The study showed that Ampligen, in combination with an anti-PD-L1 checkpoint inhibitor, significantly improved T-cell infiltration and tumor regression in a murine pancreatic cancer model....more
GlobeNewswire • May 15, 2024
AIM ImmunoTech reported its financial results for the first quarter ended March 31, 2024. The company highlighted progress in its clinical trials for Ampligen in pancreatic cancer and Long COVID, maintained a solid cash position, and reiterated its focus on advancing its development pipeline....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AIM ImmunoTech, are just a search away.